Arginase inhibitors and methods of use

US12240867B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Abdelghani Achab · Melrose, US
• Matthew L. Childers · Medfield, US
• Jared N. Cumming · Garwood, US
• Symon Gathiaka · Waltham, US
• Charles A. Lesburg · Newton, US
• Derun Li · Dedham, US
• Min Lu · San Diego, US
• Matthew J. Mitcheltree · Cambridge, US
• Anandan Palani · Bound Brook, US
• Rachel L. Palte · Melrose, US
• Hongjun Zhang · Waterloo, CA

Key dates

• Filing date: Dec 13, 2019
• Grant date: Mar 4, 2025
• Expiry date: Jan 2, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.